CRP has little incremental value over traditional cardiovascular risk factors in risk stratification.
Farkouh
Michael E
ME
Mount Sinai Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA. michael.farkouh@mssm.edu
Bansilal
Sameer
S
Mathew
Verghese
V
D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000187:drug effects / Q000502:physiology*; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology* / Q000628:therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors
D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein